June 15, 2026
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
FDA approves Tzield to treat children and adolescents with stage 3 type 1 diabetes
The FDA has granted accelerated approval for teplizumab-mzwv as the first disease-modifying therapy for children and adolescents with stage 3 type 1 diabetes, according to an industry press release. As Healio previously reported, teplizumab-mzwv (Tzield, Sanofi) was originally approved by the FDA in November 2022 to delay stage 3 type 1 diabetes among children and adults with stage 2 disease. In
TL;DRAI
Sanofi's Tzield received FDA approval for pediatric type 1 diabetes stage 3, reducing C-peptide decline to 0.13 pmol/mL vs placebo in a 328-patient trial. The therapy advances autoimmune diabetes treatment, expanding disease-modifying options for children and adolescents.
555 words~3 min read
